Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) shares crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $0.98 and traded as low as $0.91. Clearside Biomedical shares last traded at $0.94, with a volume of 187,724 shares.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on CLSD shares. HC Wainwright reaffirmed a "buy" rating and set a $6.00 price target on shares of Clearside Biomedical in a research report on Thursday, November 14th. StockNews.com upgraded shares of Clearside Biomedical from a "sell" rating to a "hold" rating in a report on Thursday, December 12th. Needham & Company LLC reaffirmed a "buy" rating and set a $6.00 price target on shares of Clearside Biomedical in a research report on Wednesday, November 13th. Finally, Chardan Capital reissued a "buy" rating and issued a $6.00 price objective on shares of Clearside Biomedical in a research report on Friday, November 15th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Clearside Biomedical currently has an average rating of "Moderate Buy" and a consensus price target of $5.33.
View Our Latest Research Report on Clearside Biomedical
Clearside Biomedical Trading Up 5.6 %
The company's 50 day moving average is $0.97 and its 200-day moving average is $1.07. The stock has a market cap of $85.70 million, a PE ratio of -2.51 and a beta of 2.22.
Clearside Biomedical (NASDAQ:CLSD - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04. The business had revenue of $1.04 million during the quarter, compared to analyst estimates of $0.25 million. During the same quarter last year, the firm posted ($0.15) EPS. As a group, analysts forecast that Clearside Biomedical, Inc. will post -0.48 EPS for the current year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Clearside Biomedical stock. Geode Capital Management LLC increased its position in Clearside Biomedical, Inc. (NASDAQ:CLSD - Free Report) by 8.8% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 731,386 shares of the company's stock after purchasing an additional 59,089 shares during the period. Geode Capital Management LLC owned 0.96% of Clearside Biomedical worth $929,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 18.75% of the company's stock.
Clearside Biomedical Company Profile
(
Get Free Report)
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
See Also
Before you consider Clearside Biomedical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clearside Biomedical wasn't on the list.
While Clearside Biomedical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
